PLX Protalix BioTherapeutics, Inc.
Biological Products, (No Diagnostic Substances) · NYSE · SEC CIK 1006281 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY37.0%
TTM net income YoY281.0%
TTM EPS YoY200.0%
Revenue 3-yr CAGR10.0%
Net income 3-yr CAGR24.6%
Margins
Gross margin71.2%
Operating margin29.8%
Net margin24.3%
FCF margin17.8%
EBITDA margin31.7%
Returns
ROE30.8%
ROA20.5%
ROIC (approx.)41.0%
Asset turnover0.84x
Leverage & solvency
Liabilities / assets31.9%
Debt / equity0.00x
Current ratio3.27x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.85x
Accruals ratio3.0%
Payout ratio—
Capex / revenue2.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $21.93M | $19.90M | $33.75M | $9.12M | $17.85M | $15.66M | $10.11M | $18.22M |
| Cost of revenue | $7.88M | $7.76M | $4.13M | $4.62M | $8.32M | $5.87M | $8.18M | $3.89M |
| Gross profit | $14.05M | $12.13M | $29.62M | $4.50M | $9.53M | $9.79M | $1.93M | $14.33M |
| R&D expense | $6.92M | $4.35M | $5.43M | $5.63M | $4.47M | $5.99M | $3.48M | $4.12M |
| SG&A expense | $3.08M | $3.11M | $3.05M | $3.53M | $2.93M | $2.62M | $2.60M | $3.00M |
| Operating income | $4.05M | $4.67M | $21.15M | -$4.66M | $2.13M | $1.17M | -$4.14M | $7.21M |
| Pretax income | $4.62M | $4.86M | $21.14M | -$4.78M | $2.24M | $661,000 | -$3.73M | $7.32M |
| Income tax | $661,000 | $1.08M | $2.82M | $728,000 | -$116,000 | $497,000 | -$113,000 | $822,000 |
| Net income | $3.96M | $3.78M | $18.32M | -$5.50M | $2.35M | $164,000 | -$3.62M | $6.49M |
| EBITDA | $4.47M | $5.08M | $21.55M | -$4.27M | $2.50M | $1.53M | -$3.80M | $7.54M |
| EPS (basic) | 0.05 | 0.05 | 0.23 | — | 0.03 | 0.00 | -0.05 | — |
| EPS (diluted) | 0.05 | 0.05 | 0.22 | — | 0.03 | 0.00 | -0.05 | — |
| Weighted avg. shares (diluted) | 83.59M | 82.56M | 83.05M | — | 80.81M | 81.27M | 76.61M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $22.04M | $27.42M | $41.00M | $14.68M | $13.65M | $17.89M | $19.46M | $19.76M |
| Receivables | $13.91M | $16.50M | $2.94M | $8.84M | $14.43M | $9.44M | $4.67M | $2.91M |
| Inventory | $34.30M | $32.29M | $30.47M | $25.73M | $21.25M | $21.13M | $19.51M | $21.24M |
| Current assets | $98.87M | $92.22M | $86.36M | $66.67M | $66.50M | $65.48M | $60.51M | $60.08M |
| PP&E, net | $5.77M | $5.47M | $5.15M | $4.88M | $4.72M | $4.75M | $4.72M | $4.59M |
| Total assets | $118.24M | $110.34M | $102.34M | $82.35M | $82.26M | $78.49M | $73.89M | $73.42M |
| Current liabilities | $30.23M | $31.39M | $27.39M | $26.52M | $21.95M | $24.09M | $24.32M | $25.62M |
| Total liabilities | $37.69M | $38.93M | $35.11M | $34.12M | $29.36M | $28.58M | $28.68M | $30.21M |
| Shareholders' equity | $80.55M | $71.40M | $67.23M | $48.23M | $52.91M | $49.90M | $45.21M | $43.21M |
| Shares outstanding | — | — | — | 80.43M | — | — | — | 75.85M |
| Cash flow statement | ||||||||
| Operating cash flow | $3.90M | -$10.40M | $22.02M | $2.03M | -$3.73M | -$5.23M | -$5.06M | $3.99M |
| Capital expenditure | $737,000 | $593,000 | $761,000 | $403,000 | $498,000 | $431,000 | $306,000 | $425,000 |
| Free cash flow | $3.17M | -$10.99M | $21.26M | $1.63M | -$4.23M | -$5.66M | -$5.36M | $3.57M |
| Investing cash flow | -$13.81M | -$3.63M | $4.22M | -$1.11M | -$504,000 | -$438,000 | -$312,000 | -$15.32M |
| Financing cash flow | $4.58M | $0 | $150,000 | $146,000 | $0 | $4.10M | $5.08M | $3.63M |
| Depreciation & amortization | $421,000 | $406,000 | $404,000 | $387,000 | $372,000 | $360,000 | $346,000 | $334,000 |
| Stock-based compensation | $601,000 | $398,000 | $532,000 | $732,000 | $598,000 | $427,000 | $540,000 | $654,000 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.